JP6355921B2 - コカイン嗜癖の治療 - Google Patents

コカイン嗜癖の治療 Download PDF

Info

Publication number
JP6355921B2
JP6355921B2 JP2013527062A JP2013527062A JP6355921B2 JP 6355921 B2 JP6355921 B2 JP 6355921B2 JP 2013527062 A JP2013527062 A JP 2013527062A JP 2013527062 A JP2013527062 A JP 2013527062A JP 6355921 B2 JP6355921 B2 JP 6355921B2
Authority
JP
Japan
Prior art keywords
disulfiram
selegiline
cocaine
inhibitor
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013527062A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013536837A (ja
JP2013536837A5 (enExample
Inventor
レーダーマン，セス
ハリス，ハーバート
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tonix Pharmaceuticals Inc
Original Assignee
Tonix Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tonix Pharmaceuticals Inc filed Critical Tonix Pharmaceuticals Inc
Publication of JP2013536837A publication Critical patent/JP2013536837A/ja
Publication of JP2013536837A5 publication Critical patent/JP2013536837A5/ja
Application granted granted Critical
Publication of JP6355921B2 publication Critical patent/JP6355921B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2013527062A 2010-09-01 2011-08-31 コカイン嗜癖の治療 Expired - Fee Related JP6355921B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37909510P 2010-09-01 2010-09-01
US61/379,095 2010-09-01
PCT/US2011/001529 WO2012050594A1 (en) 2010-09-01 2011-08-31 Treatment for cocaine addiction

Publications (3)

Publication Number Publication Date
JP2013536837A JP2013536837A (ja) 2013-09-26
JP2013536837A5 JP2013536837A5 (enExample) 2014-09-25
JP6355921B2 true JP6355921B2 (ja) 2018-07-11

Family

ID=45938591

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013527062A Expired - Fee Related JP6355921B2 (ja) 2010-09-01 2011-08-31 コカイン嗜癖の治療

Country Status (9)

Country Link
US (1) US20130165511A1 (enExample)
EP (2) EP2611440B1 (enExample)
JP (1) JP6355921B2 (enExample)
KR (1) KR20130132774A (enExample)
AU (3) AU2011314358B2 (enExample)
CA (1) CA2809966C (enExample)
DK (1) DK2611440T3 (enExample)
PT (1) PT2611440T (enExample)
WO (1) WO2012050594A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE037281T2 (hu) * 2009-11-20 2018-08-28 Tonix Pharma Holdings Ltd Eljárás és készítmény poszt-traumás stressz rendellenesség tüneteinek kezelésére ciklobenzaprin alkalmazásával
US20110319389A1 (en) 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
US11998516B2 (en) 2011-03-07 2024-06-04 Tonix Pharma Holdings Limited Methods and compositions for treating depression using cyclobenzaprine
SMT202000045T1 (it) 2013-03-15 2020-05-08 Tonix Pharma Holdings Ltd Formulazioni eutettiche di ciclobenzaprina cloridrato e mannitolo
CA2961822A1 (en) 2014-09-18 2016-03-24 Tonix Pharma Holdings Limited Eutectic formulations of cyclobenzaprine hydrochloride
CA3083341C (en) 2017-12-11 2024-05-28 Tonix Pharma Holdings Limited Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
WO2020194058A1 (en) 2019-03-26 2020-10-01 Tonix Pharma Holdings Limited Salt forms of s-(n, n-diethylcarbamoyl)glutathione
US11724486B2 (en) * 2019-07-09 2023-08-15 Kyndryl, Inc. Printing customized medication based on current user data and medical records of the user

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3155584A (en) 1962-12-03 1964-11-03 Abbott Lab Compositions and method of inhibiting monoamine oxidase and treating hypertension
SE404186B (sv) 1975-06-09 1978-09-25 Astra Laekemedel Ab Forfarande for framstellning av cyklopropanolderivat
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
WO1992021333A2 (en) * 1991-05-24 1992-12-10 Pharmavene, Inc. Treatment of drug withdrawal symptoms and drug craving with type b monoamine oxidase inhibitors
US5204369A (en) 1991-07-01 1993-04-20 The Endowment For Research In Human Biology Method for the inhibition of aldh-i useful in the treatment of alcohol dependence or alcohol abuse
US6319954B1 (en) 1995-01-13 2001-11-20 Somerset Pharmaceuticals, Inc. S-(+)-desmethylselegiline and its use in the therapeutic methods and pharmaceutical compositions
BR9501972A (pt) 1995-05-09 1997-08-26 Tostes Luiz Roberto Mallat Composição farmacêutica metodo para tratamento de dependência ou abuso de álcool e método para tratamento de distúrbios psiquiátricos geneticamente relacionados ao alcoolismo
CA2244253C (en) 1996-03-15 2002-11-12 Somerset Pharmaceuticals, Inc. Method for preventing and treating peripheral neuropathy by administering selegiline
US6255497B1 (en) 1997-04-29 2001-07-03 The Endowment For Research In Human Biology, Inc. Method for the inhibition of ALDH-I useful in the treatment of alcohol dependence or alcohol abuse
CA2308453A1 (en) 1997-10-28 1999-05-06 Schering Corporation Method of reducing craving in mammals
DE69932427T2 (de) 1998-05-12 2007-02-22 The Endowment for Research in Human Biology, Inc., Boston Verfahren und testen verwendbar bei der behandlung von alkoholabhängigkeit oder -missbrauch
FR2788982B1 (fr) 1999-02-02 2002-08-02 Synthelabo Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique
AU2002348135A1 (en) * 2001-10-31 2003-05-12 Recovery Pharmaceuticals, Inc. Methods for the treatment of addiction
CA2463987C (en) * 2001-11-05 2011-03-08 Seth Lederman Compositions and methods for increasing compliance with therapies using aldehyde dehydrogenase inhibitors and treating alcoholism
US8216609B2 (en) * 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
CA2414500A1 (en) * 2002-12-17 2004-06-17 Purepharm Inc. Agonist-aversive combination medicines
US20080078382A1 (en) * 2006-09-20 2008-04-03 Lemahieu Edward Methods and Systems of Delivering Medication Via Inhalation

Also Published As

Publication number Publication date
AU2016238908A1 (en) 2016-10-20
JP2013536837A (ja) 2013-09-26
AU2011314358A1 (en) 2013-04-04
WO2012050594A1 (en) 2012-04-19
AU2016238908B2 (en) 2018-04-05
AU2011314358B2 (en) 2016-07-07
US20130165511A1 (en) 2013-06-27
AU2018204813A1 (en) 2018-07-19
CA2809966C (en) 2019-01-08
DK2611440T3 (en) 2017-05-15
CA2809966A1 (en) 2012-04-19
EP2611440A1 (en) 2013-07-10
EP2611440A4 (en) 2014-02-19
KR20130132774A (ko) 2013-12-05
EP3170499A1 (en) 2017-05-24
PT2611440T (pt) 2017-04-26
EP2611440B1 (en) 2017-02-01

Similar Documents

Publication Publication Date Title
JP6355921B2 (ja) コカイン嗜癖の治療
JP4097285B2 (ja) 種々の頑固な疾患の治療のための医薬の製造に有用な組成物
TWI776407B (zh) 激動劑形成之調配物及使用其之方法
US20020019421A1 (en) Compositions and therapy for substance addiction
US8481599B2 (en) Compositions and methods for increasing compliance with therapies using aldehyde dehydrogenase inhibitors and treating alcoholism
MXPA02001568A (es) Ciclobenzaprina para tratar trastornos de ansiedad generalizada y composiciones de la misma.
AU2002354017A1 (en) Compositions and methods for increasing compliance with therapies using aldehyde dehydrogenase inhibitors and treating alcoholism
Celikyurt et al. Serotonin noradrenaline reuptake inhibitors (SNRIs)
TW202506129A (zh) 維貝隆（ｖｉｂｅｇｒｏｎ）用於治療膀胱過動症之用途
WO2010112530A1 (en) Pipamperone and a second agent in treating mood and anxiety disorders
Cheer et al. Fluvoxamine: a review of its therapeutic potential in the management of anxiety disorders in children and adolescents
US20020168403A1 (en) Compositions and therapy for substance addiction
Curran Duloxetine: in patients with fibromyalgia
HK1186661B (en) Treatment for cocaine addiction
HK1186661A (en) Treatment for cocaine addiction
Dean Illicit drugs and drug interactions
JP2005306882A (ja) 感情的不安定の治療のための医薬の製造に有用な組成物
JP4372723B2 (ja) 慢性疼痛の治療のための医薬の製造に有用な組成物
JP2007501245A (ja) メタボリックシンドロームを治療するための方法
MX2014002965A (es) Combinaciones que comprenden un modulador del receptor de s1p.
Schweitzer Excessive and drugs sleepiness due to medications
NZ614725B2 (en) Methods and compositions for treating depression using cyclobenzaprine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140808

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140808

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150623

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150918

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151023

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20151225

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20161003

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180406

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180613

R150 Certificate of patent or registration of utility model

Ref document number: 6355921

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees